TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04067245

Intervention type: DEVICE
Group type: OTHER
Intervention: Tetrasodium EDTA catheter lock solution
Description: Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
Study: NCT03822416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
Study: NCT01610245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT01660789

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity, dietary counseling, coaching
Description: Physical activity, dietary counseling, coaching
Study: NCT03822416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase

Intervention type: OTHER
Group type: OTHER
Intervention: Information
Description: Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
Study: NCT00817219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate ointment
Description: Once daily application for 4 weeks
Study: NCT00723047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrin glue injection in fistula
Study: NCT02258347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Study: NCT02827266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
Study: NCT04640402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of low-dose (20µg/0.5ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.
Study: NCT04197492

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Radiotherapy
Description: Hypofractionated stereotactic radiotherapy (CyberKnife, 25Gy/5fx)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
Study: NCT01990391

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brazil nut flour
Description: The Brazil nut group received 13g/day of Brazil nut flour during three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (cassava flavored flour)
Description: The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
Study: NCT03876639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of emulsion
Description: Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
Study: NCT04640402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of high-dose (40µg/1.0ml) Recombinant COVID-19 vaccine (Sf9 cells) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (18-59 years) & Two dose regimen
Description: 18-59 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (18-59 years) & Three dose regimen
Description: 18-59 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of placebo(0.5ml) at the schedule of day 0, 21.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose placebo (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of placebo(0.5ml) at the schedule of day 0, 14, 28.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (60-85 years) & Two dose regimen
Description: 60-85 years group, two doses of placebo(1.0ml) at the schedule of day 0, 21.
Study: NCT03876639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of emulsion
Description: Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of physiological skin parameters
Description: Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of physiological skin parameters
Description: Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape stripping
Description: Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tape stripping
Description: Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
Study: NCT03992222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows
Description: administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
Study: NCT03769025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suboxone Remote Observed Dosing
Description: The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone Attention Control
Description: Attention control group will send a text message daily confirming that they have taken their Suboxone dose
Study: NCT04625205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PTC-01
Description: Administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PTC-01
Description: Administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PTC-01
Description: Administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PTC-01
Description: Administered via intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PTC-01
Description: Administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Administered via intravenous infusion.
Study: NCT00640562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Extended Release
Description: Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
Study: NCT01400087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-attached Colonoscopy Versus Regular Colonoscopy
Description: Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cap-attached Colonoscopy Versus Regular Colonoscopy
Description: Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
Study: NCT01384591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo losartan
Description: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo losartan
Description: Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo N-acetylcysteine
Description: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo N-acetylcysteine
Description: Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
Study: NCT01928147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI-383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01652092

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab 0.3 mg
Description: 0.3 mg/kg intravenously (IV) on days -12 through -10

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab 0.3 mg
Description: 0.3 mg/kg intravenously (IV) on days -12 through -10

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: cyclophosphamide 50 mg/kg IV on days -9 through -6

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg.
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose.
Study: NCT04640402

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: High-dose placebo (60-85 years) & Three dose regimen
Description: 60-85 years group, three doses of placebo(1.0ml) at the schedule of day 0, 14, 28.
Study: NCT04225143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urostim bilateral
Description: Treatment by bilateral neurostimulation of the tibial nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urostim unilateral
Description: Treatment by unilateral neurostimulation of the tibial nerve
Study: NCT04303637

Intervention type: BEHAVIORAL
Intervention: Phone use
Description: Objective and subjective reports of smartphone use (e.g., number of hours, number of pick-ups, how phones are used)
Study: NCT01806792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate combine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Risedronate)
Study: NCT00463437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose.
Study: NCT01806792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for risedronate combine)
Study: NCT01652092

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine phosphate 40 mg
Description: 40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: 140 mg/m\^2 IV on day -3
Study: NCT03469674

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
Study: NCT01652092

Intervention type: DRUG
Group type: OTHER
Intervention: Alemtuzumab 0.2 mg
Description: 0.2 mg/kg intravenously (IV) on days -14 through -10

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
Study: NCT01554813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
Study: NCT01652092

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine phosphate 30 mg
Description: fludarabine 30 mg/m\^2 IV on days -8 through -4

Intervention type: DRUG
Group type: OTHER
Intervention: MESNA
Description: administered as per the standard institutional protocol.
Study: NCT01554813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza split vaccine of 15 μg HA
Description: 558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza split vaccine
Description: 280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
Study: NCT02158598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D chewable tablet supplementation
Study: NCT02233985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Chloride
Description: Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Study: NCT02403947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.